Targeting the Histamine H-4 Receptor: Future Drugs for Inflammatory Diseases

Autor(es)

Correa, Michelle Fidelis ^[1] ; dos Santos Fernandes, Joao Paulo ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Dept Ciencias Farmaceut, Rua Sao Nicolau 210, BR-09913030 Diadema, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CURRENT ORGANIC CHEMISTRY; v. 22, n. 17, p. 1663-1672, 2018.
• Citações Web of Science: 1

Resumo

Background: Histamine is a chemical transmitter widely distributed in the human body. It exerts its effects through the interaction with histaminergic receptors (H1R to H4R). The H4R is mainly expressed in hematopoietic cells, especially those involved in immune and inflammatory responses, and thus it is an important target for novel anti-inflammatory agents for the treatment of disorders such as asthma, dermatitis, rheumatoid arthritis, peritonitis, inflammatory bowel disease and allergic rhinitis. Current pharmacological therapy for the treatment of such inflammatory disorders includes poorly effective drugs in many cases, also causing important adverse reactions. Accordingly, the development of new drugs has been widely explored, especially those with a different mechanism of action from NSAIDs and corticosteroids. Discussion: H4R antagonists/inverse agonists have demonstrated potential anti-inflammatory properties and thus several ligands have been reported, showing efficacy in several clinical and preclinical studies. The indolcarboxamides, aminopyrimidines, quinoxalines and quinazolines have been the most critically explored scaffolds to achieve highly selective and potent antagonists/inverse agonists. These derivatives have shown in vivo activity and important contributions for the structure-activity relationship data. Conclusion: In this paper, a review of the main ligands is undertaken and reported in the literature showing in vivo anti-inflammatory activity and potential therapeutic application. (AU)

• Processo FAPESP: 16/25028-3 - Anti-histamínicos H3R/H4R como agentes pró-cognitivos: uma abordagem multialvo
• Beneficiário: João Paulo dos Santos Fernandes
• Linha de fomento: Auxílio à Pesquisa - Regular